Molecular imaging of dopamine transporters

Ageing Research Reviews
D J Brooks

Abstract

The dopamine transporter (DAT) is responsible for clearance of dopamine from the synaptic cleft after its release. Imaging DAT availability provides a measure of dopamine terminal function and a method for detecting the striatal dopamine terminal dysfunction present in idiopathic Parkinson's disease (PD) and atypical neurodegenerative parkinsonian disorders such as multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD). DAT imaging with positron emission tomography (PET) or single photon emission computed tomography (SPECT) can be used to support or refute a diagnosis of dopamine deficient parkinsonism in cases where this is unclear and rationalise a trial of dopamine replacement agents as therapy. It can also detect subclinical dopaminergic dysfunction when present in subjects at risk for PD such as relatives of patients, susceptibility gene mutation carriers, and subjects with late onset hyposmia or sleep disorders. The presence of normal DAT availability on imaging can help categorise "subjects without evidence of dopamine deficiency" (SWEDDs) who on occasion mimic PD and include dystonic tremors, drug-induced and psychogenic parkinsonism in their ranks. Reduced levels of bas...Continue Reading

References

Jul 1, 1990·Trends in Neurosciences·G E Alexander, M D Crutcher
Aug 1, 1994·Brain : a Journal of Neurology·K P Bhatia, C D Marsden
Oct 1, 1996·Brain : a Journal of Neurology·A D LawrenceT W Robbins
Dec 5, 2000·Movement Disorders : Official Journal of the Movement Disorder Society·W PirkerT Brücke
Apr 3, 2002·JAMA : the Journal of the American Medical Association·UNKNOWN Parkinson Study Group
Oct 8, 2003·Movement Disorders : Official Journal of the Movement Disorder Society·Paola P Piccini
Jan 18, 2005·Journal of Neurology, Neurosurgery, and Psychiatry·H NagayamaY Katayama
Jan 26, 2005·Neurology·B RavinaR Holloway
Oct 21, 2005·Neurology·I G McKeithUNKNOWN Consortium on DLB
Nov 2, 2006·Movement Disorders : Official Journal of the Movement Disorder Society·Vicky L MarshallDonald G Grosset
Nov 8, 2006·Nuclear Medicine Communications·Vicky L MarshallDonald G Grosset
Aug 23, 2007·Movement Disorders : Official Journal of the Movement Disorder Society·Susanne A SchneiderKailash P Bhatia
Sep 21, 2007·Neurology·UNKNOWN Parkinson Study Group PRECEPT Investigators
Jan 2, 2009·The British Journal of Psychiatry : the Journal of Mental Science·John T O'BrienUNKNOWN DLB Study Group
Mar 3, 2009·Journal of Neurology·Michele TinazziSarah Ottaviani
Mar 12, 2009·Journal of Neurology, Neurosurgery, and Psychiatry·L Silveira-MoriyamaA J Lees
Oct 2, 2009·Movement Disorders : Official Journal of the Movement Disorder Society·Fabiana NovellinoAldo Quattrone
Nov 21, 2012·Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging·Giorgio TregliaGiorgio Fagioli
Apr 25, 2014·Neurology·Kenneth MarekUNKNOWN Parkinson Study Group PRECEPT Investigators
Nov 29, 2014·The British Journal of Psychiatry : the Journal of Mental Science·Zuzana WalkerUNKNOWN DaTSCAN DLB Phase 4 Study Group
Jul 26, 2015·Brain : a Journal of Neurology·Zahi QamhawiNicola Pavese

❮ Previous
Next ❯

Citations

Dec 29, 2017·Neuroscience Bulletin·Zhen-Yang LiuJian Wang
Mar 25, 2018·Acta Neurologica Scandinavica·L-L BuJ Wang
Jun 16, 2018·Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging·Manuela MatesanDavid Lewis
Aug 3, 2017·American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics·Angélica Salatino-OliveiraMara H Hutz
Sep 20, 2018·Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging·Yeona KangP David Mozley
Feb 12, 2019·American Journal of Medical Genetics. Part C, Seminars in Medical Genetics·Rebecca C Knickmeyer, Stephen R Hooper
Jul 16, 2019·Journal of Parkinson's Disease·Diane StephensonUNKNOWN Critical Path for Parkinson’s Consortium
Nov 30, 2019·European Journal of Nuclear Medicine and Molecular Imaging·Aline DelvaKoen Van Laere
May 14, 2019·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·Daniela PeraniUNKNOWN IMBI Brain Imaging Working Group
Nov 8, 2017·Clinical Nuclear Medicine·Sule TinazGeorge Zubal
Aug 15, 2020·Annals of Clinical and Translational Neurology·Yanyan KongYihui Guan
May 28, 2019·Frontiers in Medicine·Sylvie ChalonMaria-Joao Ribeiro
Jun 26, 2020·Frontiers in Aging Neuroscience·Sara BelloliMaria Carla Gilardi
Aug 9, 2019·Journal of Neuroscience Research·Karina S VitanovaDamian M Cummings
Sep 15, 2018·Frontiers in Neuroscience·Fatemeh N Emamzadeh, Andrei Surguchov
Feb 6, 2021·Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia·Michaela KaiserovaPetr Kanovsky
Feb 17, 2021·PET Clinics·Kirk A Frey, Nicolaas I L J Bohnen
Oct 15, 2020·International Journal of Molecular Sciences·Maria RicciOrazio Schillaci
Oct 17, 2018·Seminars in Nuclear Medicine·Baijayanta Maiti, Joel S Perlmutter
Apr 9, 2021·European Journal of Nuclear Medicine and Molecular Imaging·Xuehan HuXiaoli Lan
Jun 21, 2017·Trends in Pharmacological Sciences·Lina Leinartaité, Per Svenningsson
Jul 27, 2021·Frontiers in Aging Neuroscience·Upasana GangulySasanka Chakrabarti
Mar 27, 2020·Current Radiopharmaceuticals·Viviana FrantellizziGiuseppe De Vincentis

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal ganglia in Parkinson's disease (MDS)

The basal ganglia is comprised of the neostriatum, the external and internal pallidal segments, the subthalamic nucleus, the substantia nigra pars reticulata, and the pars compacta of the substantia nigra. The basal ganglia circuitry is responsible for the correct execution of voluntary movements and is implicated in Parkinson's disease. Here is the latest research investigating the basal ganglia in Parkinson's disease.

Alpha-Synuclein Aggregation (MDS)

Alpha-synucleins are small proteins that are believed to restrict the mobility of synpatic vesicles and inhibit neurotransmitter release. Aggregation of these proteins have been linked to several types of neurodegenerative diseases including dementia with Lewy bodies and Parkinson's disease. Here is the latest research on α-synuclein aggregation.

Alzheimer's Disease: Neuroimaging

Neuroimaging can help identify pathological hallmarks of Alzheimer's disease (AD). Here is the latest research on neuroimaging modalities, including magnetic resonance imaging and positron emission tomography, in AD.

Atypical Parkinsonism (MDS)

Atypical Parkinsonism presents with the same signs and symptoms of Parkinson's disease, but do not respond to typical Parkionson's disease treatment with levodopa. Atypical Parkinsonism is thought to be associated with abnormal protein buildup within brain cells. Here is the latest on Atypical Parkinsonism.

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.